These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38324144)

  • 1. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.
    Esposito S; Pagliano P; De Simone G; Guarino A; Pan A; Brambilla P; Mastroianni C; Lichtner M; Brugnaro P; Carretta A; Santantonio T; Brindicci G; Carrega G; Montagnani F; Lapadula G; Spolti A; Luzzati R; Schiaroli E; Scaglione V; Pallotto C; Tacconi D; Quintieri F; Trecarichi E;
    Infection; 2024 Feb; ():. PubMed ID: 38324144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Use of Dalbavancin for Off-Label Indications.
    Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
    Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
    Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
    Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
    Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
    Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of long-acting antibiotics in the clinical practice: a narrative review.
    Micheli G; Chiuchiarelli M; Taccari F; Fantoni M
    Infez Med; 2023; 31(4):449-465. PubMed ID: 38075413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
    Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
    Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
    Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel G; Silverman M; Malhotra J; Baxter M; Rahimi R; Irfan N; Girouard G; Dhami R; Kucey M; Stankus V; Schmidt K; Poulin S; Connors W; Tascini C; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2024 Jun; 38():154-157. PubMed ID: 38908823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
    Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label use of dalbavancin in children: a case series.
    Gamell A; Velasco-Arnaiz E; López-Ramos MG; Ríos-Barnés M; Simó-Nebot S; Fumadó V; Noguera-Julián A; Fortuny C
    J Antimicrob Chemother; 2024 Jul; ():. PubMed ID: 38958260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
    Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
    Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant
    Mazzitelli M; Gatti M; Scaglione V; Mengato D; Trevenzoli M; Sattin A; Pea F; Cattelan AM
    Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.